2012-02-29 09:53 Cobra Biologics Cobra Biologics today announces that it has signed an agreement with a clinical stage biotechnology company to produce a Drug Substance under cGMP. The product, consisting of live bacteria, will be used for toxicology and clinical studies for treatment of a metabolic disorder. The disorder is a rare genetic disease leading to kidney failure and end stage renal disease.

2012-02-13 14:10 Cobra Biologics Cobra Biologics announces the appointment of three non-executive directors to Cobra Biologics’ board, and two business development managers tasked with driving continued growth in Europe and North America.The appointment of three non-executive directors, Elisabeth Lindner, Professor Carl Johan Sundberg and Jinyue Wang, further reinforces the business acumen across the Cobra Biologics’ board.

2012-01-16 11:48 Scalae AB

2011-10-31 13:22 SamInvest Mitt AB Cobra Biologics, internationell tillverkare av biologiska läkemedel, blir ny ägare till Unitech Pharma i Matfors genom förvärv av 100 procent av aktierna i bolaget.

2011-10-31 12:00 Cobra Biologics Cobra Biologics, internationell tillverkare av biologiska läkemedel, blir ny ägare till Unitech Pharma i Matfors genom förvärv av 100 procent av aktierna i bolaget.

2011-10-27 15:31 Scalae AB

2011-10-10 07:14 Onrox Onrox AB kommer att medverka på The Evertiq Convention, TEC, den 14 oktober. TEC hålls på Scandic Star Hotel i Lund mellan kl 09,30 - 17,00 Onrox AB kommer också att medverka på Subcontractor mellan den 8 - 11 november i Jönköping. Onrox finns i monter D01:50

2011-09-28 14:35 Scalae AB

2011-06-09 10:00 Cobra Biologics Unitech Pharma AB has entered a contract manufacturing agreement with the Uppsala-based company Immunsystem for the drug product manufacturing of Anti-Pseudomonas IgY. In a couple of months Immunsystem will start a phase III study for treatment of cystic fibrosis (CF) patients.